Qiagen (NYSE:QGEN) Issues Q2 Earnings Guidance

Qiagen (NYSE:QGENGet Free Report) updated its second quarter earnings guidance on Thursday. The company provided EPS guidance of $0.52 for the period, compared to the consensus EPS estimate of $0.51. The company issued revenue guidance of $495 million, compared to the consensus revenue estimate of $496.06 million.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Stifel Nicolaus reduced their target price on shares of Qiagen from $55.00 to $45.00 and set a hold rating on the stock in a research report on Wednesday, May 1st. Morgan Stanley upgraded shares of Qiagen from an equal weight rating to an overweight rating and boosted their price objective for the stock from $49.48 to $51.00 in a report on Friday, February 16th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Qiagen presently has an average rating of Moderate Buy and an average price target of $50.95.

Check Out Our Latest Analysis on QGEN

Qiagen Stock Performance

Shares of QGEN stock opened at $44.85 on Friday. The stock has a market capitalization of $10.23 billion, a price-to-earnings ratio of 30.07, a PEG ratio of 3.79 and a beta of 0.42. Qiagen has a one year low of $34.74 and a one year high of $47.70. The company’s 50-day simple moving average is $42.68 and its 200-day simple moving average is $43.56. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84.

Qiagen (NYSE:QGENGet Free Report) last released its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The company had revenue of $459.00 million for the quarter, compared to the consensus estimate of $453.91 million. During the same quarter last year, the business posted $0.53 EPS. Qiagen’s quarterly revenue was down 5.4% compared to the same quarter last year. Equities analysts anticipate that Qiagen will post 2.14 earnings per share for the current fiscal year.

About Qiagen

(Get Free Report)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Read More

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.